Abstract library

54 results for "drugs".
#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture
Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Aura Dulcinea Herrera-Martínez
#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Kosmas Daskalakis
#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience
Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego
#587 First in vitro study of Human GastroEnteroPancreatic-Neuroendocrine Tumors: comparative effect of Octreotide, Pasireotide and Everolimus.
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference:
Category: Basic
Presenting Author: MD Manuela Albertelli
#752 First In Vitro Study of Human Gastroenteropancreatic Neuroendocrine Tumors: Comparative Effect of Octreotide, Pasireotide and Everolimus
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Prof. Diego Ferone
#2008 Preliminary Evaluation of Influence of Different Targeted Drugs of Vascular Endothelial Growth Factor Signaling Pathway on the Proliferation of Neuroendocrine Neoplasm Cell Lines
Introduction: Sunitinib and bevacizumab are intracellular and extracellular inhibitor of vascular endothelial growth factor(VEGF) pathway respectively, the influence of both of which on the proliferation of neuroendocrine neoplasm (NEN) cell lines in vitro was not known yet.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Y, Chen M, ...
#1097 Epigenetic Manipulation of the Somatostatin Receptor Type 2 in Neuroendocrine Tumor Cells
Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment in patients with neuroendocrine tumors (NET). However, variability in tumoral sst2 expression might lead to variability in response. Epidrugs could increase sst2 levels and improve response to somatostatin analogues (SSA).
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Marije Jildau Veenstra
Keywords: NET, sst2, epidrug, signaling
#256 Evaluation of the Association Between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
Introduction: Bone mineral density (BMD) and fractures are influenced by diet, activity, drugs and hormones. Recent studies highlight an inverse relationship between serotonin and BMD.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Maralyn R Druce
#547 Insulin Autoimmune Syndrome Mimicking Insulinoma: A Challenging Diagnosis
Introduction: Insulin autoimmune syndrome (IAS) is a rare condition characterized by hypoglycemia due to autoantibodies against endogenous insulin. It is correlated, in approximately 50% of cases, to specific drugs intake. Hypoglycemia occurs typically during the late post-prandial period.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#1008 STZ-Based Chemotherapy is Associated with Durable Response Rate in Pancreatic NET as 1st or 2nd Line Treatment
Introduction: The role of chemotherapy for pancreatic neuroendocrine tumors (pNETs) is controversially discussed. Objective response rates (RR) with streptozocin (STZ)-based chemotherapy are variable. Novel targeted drugs have recently been approved.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Lisa-Marie Dilz